Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: bivatuzumab mertansine
Sponsor: Boehringer Ingelheim